JP2023504195A5 - - Google Patents
Info
- Publication number
- JP2023504195A5 JP2023504195A5 JP2022534221A JP2022534221A JP2023504195A5 JP 2023504195 A5 JP2023504195 A5 JP 2023504195A5 JP 2022534221 A JP2022534221 A JP 2022534221A JP 2022534221 A JP2022534221 A JP 2022534221A JP 2023504195 A5 JP2023504195 A5 JP 2023504195A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025264280A JP2026048892A (ja) | 2019-12-06 | 2025-12-18 | 状態および疾患の処置のためのアンチセンスオリゴマー |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945048P | 2019-12-06 | 2019-12-06 | |
| US62/945,048 | 2019-12-06 | ||
| US202062993971P | 2020-03-24 | 2020-03-24 | |
| US62/993,971 | 2020-03-24 | ||
| PCT/US2020/063157 WO2021113541A1 (en) | 2019-12-06 | 2020-12-03 | Antisense oligomers for treatment of conditions and diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025264280A Division JP2026048892A (ja) | 2019-12-06 | 2025-12-18 | 状態および疾患の処置のためのアンチセンスオリゴマー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023504195A JP2023504195A (ja) | 2023-02-01 |
| JP2023504195A5 true JP2023504195A5 (https=) | 2023-12-07 |
| JPWO2021113541A5 JPWO2021113541A5 (https=) | 2023-12-07 |
Family
ID=76222665
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534221A Pending JP2023504195A (ja) | 2019-12-06 | 2020-12-03 | 状態および疾患の処置のためのアンチセンスオリゴマー |
| JP2025264280A Pending JP2026048892A (ja) | 2019-12-06 | 2025-12-18 | 状態および疾患の処置のためのアンチセンスオリゴマー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025264280A Pending JP2026048892A (ja) | 2019-12-06 | 2025-12-18 | 状態および疾患の処置のためのアンチセンスオリゴマー |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230116704A1 (https=) |
| EP (1) | EP4069256A4 (https=) |
| JP (2) | JP2023504195A (https=) |
| KR (1) | KR20220113743A (https=) |
| CN (1) | CN115087452A (https=) |
| AU (1) | AU2020395835A1 (https=) |
| BR (1) | BR112022010882A2 (https=) |
| CA (1) | CA3159162A1 (https=) |
| IL (1) | IL293531A (https=) |
| MX (1) | MX2022006858A (https=) |
| WO (1) | WO2021113541A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| WO2021174036A1 (en) * | 2020-02-28 | 2021-09-02 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating scn1a expression |
| BR112022022889A2 (pt) | 2020-05-11 | 2023-04-04 | Stoke Therapeutics Inc | Oligômeros antissentido de opa1 para tratamento de condições e doenças |
| EP4392562A4 (en) * | 2021-08-27 | 2025-09-24 | Ionis Pharmaceuticals Inc | COMPOUNDS AND METHODS FOR MODULATING SCN1A EXPRESSION |
| EP4562020A2 (en) * | 2022-07-29 | 2025-06-04 | Stoke Therapeutics, Inc. | Compounds for treatment of conditions and diseases |
| JP2025526712A (ja) * | 2022-08-11 | 2025-08-15 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその方法 |
| EP4665407A2 (en) * | 2023-02-14 | 2025-12-24 | Stoke Therapeutics, Inc. | Antisense oligomer formulations |
| MX2025013084A (es) * | 2023-05-03 | 2026-02-03 | Stoke Therapeutics Inc | Compuestos y métodos para tratar sujetos humanos |
| WO2026036032A1 (en) * | 2024-08-09 | 2026-02-12 | Amylyx Pharmaceuticals, Inc. | Formulations containing antisense oligonucleotides targeting calpain-2 |
| WO2026052819A1 (en) * | 2024-09-06 | 2026-03-12 | Ospedale San Raffaele S.R.L. | Gene therapy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6503756B1 (en) * | 2000-09-22 | 2003-01-07 | Isis Pharmaceuticals, Inc. | Antisense modulation of syntaxin 4 interacting protein expression |
| WO2011163499A2 (en) * | 2010-06-23 | 2011-12-29 | Opko Curna, Llc | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
| EP3933041B1 (en) * | 2015-12-14 | 2024-01-31 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant retardation |
| SG11202001590RA (en) * | 2017-08-25 | 2020-03-30 | Stoke Therapeutics Inc | Antisense oligomers for treatment of conditions and diseases |
| GB2610100B (en) * | 2017-10-23 | 2023-08-16 | Stoke Therapeutics Inc | Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases |
| WO2019224864A1 (ja) * | 2018-05-21 | 2019-11-28 | 国立研究開発法人理化学研究所 | Ｓｃｎ１ａ遺伝子の発現増強法とそれによるドラベ症候群の治療法 |
| KR20210134003A (ko) * | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
-
2020
- 2020-12-03 BR BR112022010882A patent/BR112022010882A2/pt unknown
- 2020-12-03 JP JP2022534221A patent/JP2023504195A/ja active Pending
- 2020-12-03 WO PCT/US2020/063157 patent/WO2021113541A1/en not_active Ceased
- 2020-12-03 CN CN202080095947.9A patent/CN115087452A/zh active Pending
- 2020-12-03 AU AU2020395835A patent/AU2020395835A1/en active Pending
- 2020-12-03 EP EP20897381.8A patent/EP4069256A4/en active Pending
- 2020-12-03 CA CA3159162A patent/CA3159162A1/en active Pending
- 2020-12-03 KR KR1020227023111A patent/KR20220113743A/ko active Pending
- 2020-12-03 MX MX2022006858A patent/MX2022006858A/es unknown
- 2020-12-03 IL IL293531A patent/IL293531A/en unknown
-
2022
- 2022-06-03 US US17/832,182 patent/US20230116704A1/en active Pending
-
2025
- 2025-12-18 JP JP2025264280A patent/JP2026048892A/ja active Pending